{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-016883","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-05-14T12:05:14+00:00","discovered_at":"2026-05-14T12:10:00.551540+00:00","generated_at":"2026-05-14T12:25:51.244751+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Genprex diabetes gene therapy GPX-002 reverses hyperglycemia in T2D mouse model","bullets":["Preclinical data presented at ASGCT 2026 showed GPX-002 reversed hyperglycemia in Type 2 diabetic mice within 4 weeks.","Treatment improved β-cell function: increased insulin granules, improved glucose-stimulated insulin secretion vs controls.","β-cell-specific targeting (RIP-PM-GFP) also reversed hyperglycemia, indicating enhanced β-cell maturation.","Approach is translatable to humans via endoscopic retrograde cholangiopancreatography delivery to the pancreas."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016883","json":"https://secwatch.observer/filing/0001437749-26-016883.json","markdown":"https://secwatch.observer/filing/0001437749-26-016883.md","text":"https://secwatch.observer/filing/0001437749-26-016883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926016883/0001437749-26-016883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926016883/gnpx20260513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:25:51.244751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}